Trial intelligence / Profile preview

RUBIKID - Dynamic 82-Rb PET for Grading Kidney Carcinoma

2024-514085-39-00Phase 2Authorised

Sponsor: Assistance publique - Hôpitaux de Paris
Start: Aug 2025
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of rubidium-82 chloride in kidney cancer and renal cell carcinoma (RCC), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Aug 2025; status: authorised.

Drugs

rubidium-82 chloride

Conditions

kidney cancerrenal cell carcinoma (RCC)

Beyond the preview

Go deeper on 2024-514085-39-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514085-39-00.